Please login to the form below

Not currently logged in
Email:
Password:

Eisai fails to win NICE backing for breast cancer drug Halaven

UK cost effectiveness body says drug has unacceptable level of side-effects

The National Institute for Health and Clinical Excellence (NICE) has recommended against the use of Eisai's breast cancer drug Halaven (eribulin) on the NHS.

Halaven is being assessed as a treatment for locally advanced or metastatic breast cancer in people whose disease has progressed after at least two chemotherapeutic regimens for advanced disease.

In final draft guidance the Institute said that although study results suggested Halaven could help patients live longer, it caused more undesirable side-effects than already recommended treatments.

The drug's most most common adverse effects are fatigue, alopecia, peripheral neuropathy, nausea, neutropenia, leukopenia and anaemia

NICE also said that Eisai had failed to adequately assess Halaven's effects on an individual's quality of life.

NICE's chief executive Sir Andrew Dillon said: “The advisory committee heard from clinical experts that in current practice, patients at this stage usually receive sequential treatment of vinorelbine, capecitabine and, more rarely, gemcitabine.

“The experts also stressed that even if eribulin were approved by NICE, it would be unlikely to replace capecitabine and vinorelbine in the established sequential pathway because of its related side effects.”

Eisai has agreed a patient access scheme with the Department of Health to make Halaven available at a discounted price, the details of which are confidential, but NICE said the drug was still not cost-effective enough even at this lower price.

The most plausible cost per quality adjusted life year (QALY) gained of Halaven compared with 'treatment of physician's choice' was estimated by NICE to be over £68,600.

NICE's draft guidance is now open to appeal, with final guidance due to be issued in December. Until then, NHS bodies can make decisions locally on funding the drug.

17th November 2011

Share



Related Hub content

    Your search did not contain any words. Please try again.

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
CSafe Global

CSafe Global is the only global provider of a full line of cold chain solutions and is the world’s largest...

Latest intelligence

England’s clinical commissioning landscape
Who are the real masters in the new NHS?...
How will the new landscape of Hep C treatments affect patients?
The development of new therapeutic agents is set to transform the treatment of hepatitis C over the coming years....
Pharma deal watch - handshake
Pharma deals during March 2014
Deal Watch: Major pharma collaborations, acquisitions and agreements in the past month...